Farmacogenómica clínica de CYP2C8 y CYP2C9: conceptos generales y aplicación al uso de AINE
Reads0
Chats0
TLDR
Aunque la actividad CYP2C8/9 juega un papel fundamental en el metabolismo y in the respuesta clinica de muchos AINE, el uso of tecnicas farmacogenomicas no tiene la misma utilidad para todos estos farmacos.About:
This article is published in Farmacia Hospitalaria.The article was published on 2006-07-01 and is currently open access. It has received 11 citations till now.read more
Citations
More filters
Journal ArticleDOI
Gender Differences in the Pharmacokinetics of Oral Drugs
TL;DR: The final result, in general, is that women have higher plasma levels of drugs and usually these differences are reduced or abolished when data are normalized by the body weight, since both, volume of distribution and systemic clearance are influenced by it; however, there are some cases in which differences remain.
Journal ArticleDOI
Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications.
TL;DR: Existing scientific evidence supports the pharmacogenomic basis of interindividual variation in treatment response to aspirin and NSAIDs, with clinical implications for antiplatelet action, cancer chemoprevention, and drug safety.
Journal ArticleDOI
Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers
TL;DR: Results from the PK analysis suggested that the test and reference formulations of aceclofenac 100-mg tablets were bioequivalent, based on the regulatory definition.
Journal ArticleDOI
Cytochrome P450 interactions and clinical implication in rheumatology
Audrey Cayot,Davy Laroche,Anne Disson-Dautriche,Anaïs Arbault,Jean-Francis Maillefert,Paul Ornetti +5 more
TL;DR: The aim of this article is to act as a reminder of the metabolic role of membrane-bound CYP enzymes in the liver in the oxidation of drugs and the potential types of interaction, which may contribute to variations in drug metabolism and therefore modify the benefit-risk ratio of the drug.
Journal ArticleDOI
Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography-tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazole.
Thiago José Dionísio,Gabriela M. Oliveira,Marina Morettin,Flavio Augusto Cardoso de Faria,Carlos Ferreira dos Santos,Adriana Maria Calvo +5 more
TL;DR: The detection and quantification of naproxen and its metabolite will be validated, which elucidate the pharmacokinetics of this drug, thereby contributing to its proper prescription for the medical and dental interventions that cause acute pain.
References
More filters
Journal ArticleDOI
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
TL;DR: YP2C9 genotyping may identify a subgroup of patients who have difficulty at induction of warfarin therapy and are potentially at a higher risk of bleeding complications.
Journal ArticleDOI
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Mitchell K. Higashi,David L. Veenstra,L. Midori Kondo,Ann K. Wittkowsky,Sengkeo L. Srinouanprachanh,Fred M. Farin,Allan E. Rettie +6 more
TL;DR: The results of this study suggest that the CYP2C9*2 and CYP1c9*3 polymorphisms are associated with an increased risk of overanticoagulation and of bleeding events among patients in a warfarin anticoagulated clinic setting, although small numbers in some cases would suggest the need for caution in interpretation.
Journal ArticleDOI
Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review
TL;DR: The results suggest that drug therapy based on individuals' genetic makeups may result in a clinically important reduction in adverse outcomes and serve as a foundation for further research on how pharmacogenomics can reduce the incidence of adverse reactions and on the resulting clinical, societal, and economic implications.
Journal ArticleDOI
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
Theresa H. Sullivan-Klose,Burhan I. Ghanayem,Douglas A. Bell,Zhi Yi Zhang,Laurence S. Kaminsky,Gillian M. Shenfield,John O. Miners,Donald J. Birkett,Joyce A. Goldstein +8 more
TL;DR: The present data suggest that the incidence of the Leu359 allelic variant of CYP2C9 may account for the occurrence of poor metabolizers of tolbutamide.
Journal ArticleDOI
Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future
TL;DR: It is anticipated that, in the future, genotyping could be used to personalize drug treatment for vast numbers of subjects, decreasing the cost of drug treatment and increasing the efficacy of drugs and health in general.